Introduction: A variety of national and international guidelines exist around the management of carbapenem resistant Enterobacteriaceae (CREs), but some of these are several years old and do not reflect current epidemiology and they also do not necessarily give pragmatic advice around active surveillance of CREs in countries with a high burden of cases and limited resources. This paper aims to provide a best practice position paper to guide active surveillance in a variety of scenarios in these settings, and discusses which patients should be screened, what methods could be used for screening, and how results might influence infection prevention interventions., Methods: This paper was developed as a result of a series of meetings of expert opinion leaders representing the major infectious disease and infection prevention societies in Italy and having the endorsement of AMCLI (Italian Association of Clinical Microbiology) and SITA (Italian Society for Anti-infective Therapy). There was no attempt to undertake a full systematic review of the evidence, as it was felt that this was inadequate to inform a pragmatic view on the best way forward based on current epidemiology and infection rates., Key Recommendations: Key recommendations focus on the urgent need to promote measures to prevent transmission and infection, focusing on high risk patients and clinical areas, as well as outbreak situations. Active surveillance leading to appropriate infection prevention precautions plays a major role in this., Conclusions: There are limited national or international guidelines giving pragmatic advice on the most appropriate measures for active surveillance and management of colonized patients in a high-burden setting such as Italy. While individual hospitals and regions will need to formulate their own policies based on local epidemiology, this position paper attempts to highlight current best practice in this area and provide pragmatic advice for clinicians, infection prevention staff, and healthcare managers., Competing Interests: Competing interestsFor activities outside of the submitted work, SA has received fees as speaker from ADA, Biomerieux, Cepheid, MB has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas Pharma, AstraZeneca, Bayer, Biomerieux, Cepheid, Cidara, Pfizer, Menarini, MSD, Nabriva, Paratek, Roche, Shionogi, Tetraphase, Thermofisher and the Medicine Company, NP has received fees as speaker from MSD, Pfizer, Cepheid, Takeda, Shionogi, Angelini, Zambon, Becton & Dickinson, Johnson & Johnson, PV has served as a consultant for MSD, PFIZER, VENATORX, NABRIVA, GILEAD, THERMOFISHER and BIOMERIEUX and received payment for serving on the speaker’s bureau for MSD, PFIZER, CORREVIO and GILEAD, GMR has received honoraria for scientific advisory boards, travel and speaker’s bureau from Accelerate, Angelini, AstraZeneca, Basilea, Beckman Coulter, Biotest, Cepheid, Curetis, Elitech, Menarini, Merck, Nordic Pharma, Novartis, Pfizer, Qpex, Rempex, Roche, Thermo Fisher, VenatorX, Zambon; and research grants to the laboratory from from Accelerate, Alifax, Angelini, Arrow, AstraZeneca, Basilea, Becton-Dickinson, bioMérieux, Biotest, Cepheid, Checkpoints, Elitech, Estor, Liofilchem, Menarini, Merck, Nordic Pharma, Novartis, Pfizer, Rempex, Seegene, Shionogi, VenatorX, Zambon. PC and FT declare that they have no competing interests.